Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.